Identification of a Metabolic, Transcriptomic, and Molecular Signature of Patatin‐Like Phospholipase Domain Containing 3–Mediated Acceleration of Steatohepatitis

Bubu A. Banini, Divya P. Kumar, Sophie Cazanave, Mulugeta Seneshaw, Faridoddin Mirshahi, Prasanna K. Santhekadur, Liangsu Wang, Hong Ping Guan, Abdul M. Oseini, Cristina Alonso, Pierre Bedossa, Srinivas V. Koduru, Hae‐Ki Min, Arun J. Sanyal – 1 November 2020

Elevated Glycated Hemoglobin Is Associated With Liver Fibrosis, as Assessed by Elastography, in a Population‐Based Study of Mexican Americans

Gordon P. Watt, Isela De La Cerda, Jen‐Jung Pan, Michael B. Fallon, Laura Beretta, Rohit Loomba, Miryoung Lee, Joseph B. McCormick, Susan P. Fisher‐Hoch – 31 October 2020 – Diabetes is associated with liver disease and risk of hepatocellular carcinoma. In this study, we evaluated the association between liver fibrosis measured by transient elastography and four glucose metabolism measures in the Cameron County Hispanic Cohort, a population‐based, randomly selected cohort of Mexican American Hispanics with high rates of diabetes and liver cancer.

Treatment on the Spleen Prevents the Progression of Secondary Sarcopenia in Patients With Liver Cirrhosis

Masashi Hirooka, Yohei Koizumi, Takaaki Tanaka, Yoshiko Nakamura, Koutarou Sunago, Atsushi Yukimoto, Takao Watanabe, Osamu Yoshida, Teruki Miyake, Yoshio Tokumoto, Bunzo Matsuura, Masanori Abe, Yoichi Hiasa – 31 October 2020 – Hyperammonemia is an important stimulator of myostatin expression, a negative regulator of muscle growth. After splenectomy or partial splenic artery embolization (PSE), hyperammonemia often improves.

Nonalcoholic Fatty Liver Disease Screening in Type 2 Diabetes Mellitus Patients in the Primary Care Setting

Joana Vieira Barbosa, Michelle Lai – 31 October 2020 – Nonalcoholic fatty liver disease (NAFLD) is a major public health problem worldwide and the most common chronic liver disease. NAFLD currently affects approximately one in every four people in the United States, and its global burden is expected to rise in the next decades. Despite being a prevalent disease in the general population, only a minority of patients with NAFLD will develop nonalcoholic steatohepatitis (NASH) with advanced liver fibrosis (stage 3‐4 fibrosis) and liver‐related complications.

Subscribe to